AuraSense Therapeutics, an Evanston, IL-based biopharmaceutical company commercializing spherical nucleic acid (SNA™) constructs as gene regulation- and chemo-therapeutics for several diseases, has closed a Series B financing of undisclosed amount.
Backers include Abbott Biotech Ventures, a subsidiary of Abbott, and individual investors, including:
– Patrick Ryan, founder of Aon;
– David Walt, co-founder of Illumina;
– Eric Schmidt, Executive Chairman of Google; and
– Craig Mundie, Chief Research and Strategy Officer of Microsoft.
The company intends to use the capital to accelerate its efforts to develop its SNA platform.
Co-founded by Professors Chad A. Mirkin and C. Shad Thaxton at Northwestern University, AuraSense Therapeutics is dedicated to developing and commercializing spherical nucleic acid (SNA™) constructs as gene regulation- and chemo-therapeutics for a variety of diseases, including applications in oncology, dermatology, neurology, and for cardiovascular disorders.